The goals of this review are to discuss the pathophysiology and determinants of muscle weakness and neuromuscular dysfunction after critical illness, and to offer thoughts regarding the role of future longitudinal studies in this area.
Introduction
Understanding long-term outcomes after critical illness is crucial to improving care for patients before and after ICU discharge. Much has been learned over the past 20 years about the myriad of sequelae of critical illness. Follow-up studies of subjects with acute lung injury and other critical illnesses have demonstrated significant decrements in health-related quality of life (HRQOL), with muscle weakness and impairment of physical activity and functional status persisting in the majority of survivors for months or even years after ICU discharge [1] [2] [3] . In this article, we review the pathophysiology and determinants of muscle weakness and neuromuscular dysfunction after critical illness, and offer thoughts regarding the role of future longitudinal studies in this area.
Etiology of weakness
There are many potential contributors to weakness in survivors of critical illness. Patients may be weak at ICU admission secondary to chronic disease. For others, an acute neurological syndrome, such as Guillain-Barré syndrome or myasthenia gravis, may be the cause of critical illness. Persistent organ dysfunction resulting from critical illness may be associated with weakness and fatigue. Neuromuscular pathology acquired during critical illness (e.g. critical illness polyneuropathy and myopathy, ischemic or compression mononeuropathies) may be a significant contributor to prolonged functional impairment. Nonpathological processes, such as muscle atrophy and deconditioning associated with protracted inactivity, may also play a role in weakness after critical illness. Even in the absence of reduced muscle force, pain and psychological disturbances, such as depression and posttraumatic stress, may diminish the ability or willingness of patients to perform physical tasks.
Immobility
During critical illness most patients endure a long period of immobility. Immobility has important effects on multiple body systems including the musculoskeletal system [4] . The known effects of immobility are based on experimental animal and human studies. In one study of prolonged immobility (14 days) in healthy volunteers, investigators observed a 4% decrease in lean mass countered by a 5% increase in fat mass in the volunteers' thighs [5] . After 6 weeks of immobility, another study [6] demonstrated a 15% decrease in the cross-sectional area of the quadriceps muscle with an over 25% decrease in strength. Decreased protein synthesis in skeletal muscle is likely an important mechanism for the decrease in muscle mass during immobility [5] . These factors make immobility an important cause of weakness in ICU survivors.
Critical illness polyneuropathy and myopathy
Critical illness and its treatments are toxic to nerves and muscles and may lead to pathologic changes [7] , termed critical illness polyneuropathy (CIP) and critical illness myopathy (CIM). These conditions may occur alone or are frequently coincident: critical illness polyneuropathy and myopathy (CIPM) [8] . CIPM is common among critically ill patients, with its incidence varying by case definition and population, with a range from 30 to over 90% [9 ] . CIPM may be missed during the acute phase of critical illness when the patient is sedated, restrained, and unable to communicate, although clinicians may note weakness in withdrawal to painful stimuli, diminished deep tendon reflexes and decreased spontaneous movement. Difficulty liberating from mechanical ventilation may be the first sign of CIPM appreciated by ICU physicians.
CIP is an axonal polyneuropathy that affects both sensory and motor nerves. Physical examination of a cooperative patient may reveal distal sensory deficits, distal weakness, and preserved deep tendon reflexes. Electrophysiologic studies demonstrate decreased amplitudes of sensory and motor nerve action potentials, with normal motor unit potentials and excitability. Pathologic evaluation reveals fiber loss and primary axonal degeneration of both motor and sensory nerve fibers, most severe distally [7] .
CIM describes a spectrum of muscle pathology seen in critically ill patients. Clinical signs include flaccid tetraparesis with depressed or absent deep tendon reflexes. Sensory function is not affected. Nerve conduction studies reveal decreased amplitudes of compound muscle action potentials with preserved sensory nerve action potential. Electromyography shows small and short motor unit potentials. Direct stimulation of the muscle demonstrates reduced or absent muscle excitability [10] . Pathologic evaluation most commonly reveals thick filament loss (seen on electron microscopy) with atrophy of the type II fibers. Acute necrotizing myopathy develops less frequently with diffuse necrosis of muscle fibers.
Determinants of weakness
There are many commonly cited risk factors for neuromuscular dysfunction in critically ill patients. There are, however, important methodological limitations that impact the reliability, validity and generalizability of existing studies in this field [11 ] . Most studies have been small, retrospective, single-center investigations. Multivariable analyses to adjust for potential confounding factors in determining the independent effect of potential determinants of weakness are frequently not done or not feasible. In addition, heterogeneity in the ICU setting, patient population, and definition of neuromuscular dysfunction, prevent the direct comparison of findings between studies. As a result, it is not possible to make definitive conclusions regarding many determinants of weakness after critical illness. In this study [12] , patients with weakness also were significantly older (68 versus 59 years), but age did not have an independent effect in the multivariable analysis. Hermans et al. [13 ] reported on a prospective subanalysis (n ¼ 420) of a randomized trial of intensive insulin therapy. This analysis did not evaluate patient sex, but found that older age was negatively associated (OR 0.98, 95% CI 0.96-0.99 per year) with neuromuscular dysfunction, as defined by electroneuromyography. This finding has not been observed in other studies and could not be explained by these investigators [13 ] .
Severity of illness
Severity of illness may be a determinant of weakness in ICU survivors. De Jonghe et al. found that admission Simplified Acute Physiology Score-2 was not associated with weakness, but dysfunction in two or more organ systems during patients' ICU stay was significantly associated with weakness (OR 1.3, 95% CI 1.1-1.5 for each additional day of two or more organ failures). Other studies have also found an independent association of weakness with increased severity of illness measured using the Acute Physiology and Chronic Health Evaluation (APACHE) III and Sequential Organ Failure Assessment (SOFA) scoring systems [14, 15] . Hermans et al., however, did not find an association of severity of illness, measured using a baseline APACHE II score and a maximal SOFA score during ICU stay, with neuromuscular dysfunction after adjusting for other potential risk factors. Differences in how severity of illness is measured and modeled in analyses may contribute to differences in findings among studies.
Blood glucose and intensive insulin therapy
There is growing evidence that supports high blood glucose as a risk factor, and intensive insulin therapy as a preventive factor, for neuromuscular dysfunction after critical illness. Evidence for this hypothesis is based on sub-analyses of two large single-center randomized trials of intensive insulin therapy in medical and surgical ICU patients [13 ,16-18] , as well as several observational studies [12, 19, 20] . Since the benefit of glycemic control using intensive insulin therapy is not universally endorsed [21, 22] , the results from additional studies (VISEP and Glucontrol, results not yet published) will be helpful in understanding the effect of intensive insulin therapy on neuromuscular dysfunction [21] .
Corticosteroids
De Jonghe et al. reported a large and significant independent association of weakness with corticosteroids (OR 14.9, 95% CI 3.2-69.8). There was no significant association, however, between weakness and dose or duration of corticosteroid therapy. Other studies [14] [15] [16] 19, [23] [24] [25] have not reported any significant association of corticosteroids with weakness. Moreover, Hermans et al. [13 ] reported that the duration of steroid use was independently associated with decreased neuromuscular dysfunction in patients randomized to intensive insulin therapy (OR 0.91, 95% CI 0.86-0.97). Hermans et al. hypothesized that when blood glucose is strictly controlled, the anti-inflammatory effect of corticosteroids may benefit the neuromuscular system [13 ] .
Neuromuscular blockers
Neuromuscular blockers were not associated with weakness in three larger-sized, prospective studies that adjusted for potential confounders [12, 15, 16] . Issues related to the low total dose received in the ICU [12] , however, and the methods for modeling this exposure may have prevented full evaluation of an association of these drugs with weakness in ICU survivors. Hermans et al. found an independent association of neuromuscular blockade infusion with neuromuscular dysfunction (OR 2.0, 95% CI 1.1-4.0). A second study also found an independent association, potentially due to the larger total doses of neuromuscular blockade used in this study [25] .
Pathophysiology of critical illness polyneuropathy and myopathy
Pathologic changes of nerve and muscle acquired during critical illness, critical illness polyneuropathy and myopathy, are likely the most common causes of ICUacquired weakness. Recent studies have increased understanding of the histology and mechanisms responsible for damage to nerve and muscle in the ICU setting.
Pathogenesis of critical illness polyneuropathy
The primary pathologic finding in critical illness polyneuropathy is axonal degeneration. Additionally, it has been demonstrated that abnormal nerve conduction may exist even in the absence of structural changes to the nerve [26] [27] [28] . Axonal degeneration may be the result of factors associated with the systemic inflammatory response syndrome (SIRS) as well as treatments and consequences of critical illness. SIRS affects peripheral nerves in multiple ways. Lacking autoregulation, the blood vessels that supply peripheral nerves may be especially susceptible to hypotension, microthrombosis and other changes in the microcirculation [29, 30] . Endoneural edema also may develop [20] , which affects nerve function and decreases oxygen delivery to the nerve accelerating nerve damage. Inflammation has multiple deleterious effects on peripheral nerves [31] [32] [33] . Furthermore, septic patients have mitochondrial dysfunction, which leads to decreased ATP production [34] . Lack of energy, termed 'bioenergetic failure', induces primary axonal degeneration that is more pronounced distally in long nerves [7] . Neurotoxic medications, such as aminoglycosides, may be particularly harmful in the setting of increased capillary permeability and ongoing nerve damage. Metabolic abnormalities (respiratory acidosis, hyperkalemia) and hypoperfusion appear to contribute to abnormal nerve excitability and conduction, which in turn may predispose affected nerves to neuropathy [28] .
Pathogenesis of critical illness myopathy
Critical illness myopathy appears to be associated with increased muscle breakdown, decreased protein production and abnormal muscle repair, resulting from factors associated with critical illness (e.g., SIRS) and its side-effects (e.g., inactivity) and treatments. Other pathogenic mechanisms include derangements of energy delivery [34] and changes in the muscle membrane with primary inexcitability of muscle fibers [35] [36] [37] . These mechanisms may contribute to easy fatiguability and inability to generate normal muscle force. Muscle breakdown is induced and accelerated by inflammation and denervation, which act via multiple proteolytic systems [12, 19, 20, [38] [39] [40] [41] . Muscle can be functionally denervated in critical illness via concomitant CIP, necrosis at the motor endplate, or pharmacologic denervation with neuromuscular blocking agents [7, 42] . Inflammatory mediators also impair myofiber repair by decreasing the expression of MyoD, a gene that regulates muscle cell differentiation and myogenesis [43] . Immobility appears to potentiate this effect [44] . Corticosteroids have a powerful direct effect on skeletal muscle, and can lead to myosin loss, atrophy, and frank necrosis [45 ] . Corticosteroids also promote apoptosis in skeletal muscle, which contributes to cell and protein breakdown [46] , and decrease the synthesis of myosin [47] .
Outcomes after critical illness polyneuropathy and myopathy
A recent systematic review of 36 studies compiled the long-term outcomes of 263 patients with CIPM [48] .
Most subjects were followed for 3-6 months, but the sample included follow-up to 8 years. At hospital discharge, most patients described profound muscle weakness, which improved over time, beginning with the upper extremities. Over the course of follow-up, 68% of these subjects regained the ability to walk independently, while 28% remained severely disabled. Only two studies, however, included follow-up of the entire inception cohort, including patients who did not meet criteria for CIPM [49, 50] . These studies found that CIPM was associated with rehabilitation delays, weakness, sensory abnormalities, and severe disability at 1 year [49] . Conversely, no large studies of HRQOL after critical illness have included prospective evaluation of neuromuscular function, so the contribution of CIPM to functional disability and impaired HRQOL remains unknown.
Summary of literature review
Weakness and impaired functional status are common in ICU survivors. CIPM and deconditioning are likely important contributors, but this remains unproven. Based primarily on pathophysiologic studies, inflammation, hyperglycemia, corticosteroids, neuromuscular blocking agents, and immobility may all contribute to nerve and muscle pathology, but epidemiologic studies have not yet irrefutably confirmed any of these factors with CIPM or patient outcomes. With data on the effects of tight glycemic control with intensive insulin therapy still evolving, at present, there is no treatment or management that convincingly prevents or minimizes neuromuscular dysfunction or hastens patients' recovery after critical illness.
The role of future longitudinal studies
Despite an increase in the number and quality of studies of ICU-acquired neuromuscular dysfunction, there remain large gaps in our knowledge of fundamental aspects of the epidemiology, pathophysiology, natural history, and clinical approaches to prevent, minimize and treat weakness in survivors. Unfortunately, these types of study are difficult and expensive to perform.
Selecting patients and defining disease
Patient selection should be driven by the research question. Studies of incidence and biology of ICU-acquired neuromuscular dysfunction may be interested in enrolling all patients at risk (all ICU patients, or all patients requiring at least 3-7 days of critical care) who do not have significant antecedent neuromuscular disease. Patients who die in the hospital or in the first year after hospital discharge may still contribute significantly to this type of study. Studies interested in connecting ICUacquired weakness or neuromuscular dysfunction with longer-term outcomes would benefit from restricting enrollment to patients expected to survive hospitalization and beyond. Patients at greatest risk (e.g. septic shock), however, may have the highest mortality before and after hospital discharge [51] .
The timing and type of neuromuscular evaluation should be guided by the research question as well. Standardized physical exam [12, 52] can detect weakness and has been proposed for clinical screening and research case definition [21, 53 ] . This approach identifies patients with neuromuscular dysfunction, but it is limited in sensitivity and use [9 ] . Only patients able to follow complex commands can be evaluated; over 50% of ICU patients may not meet this criterion [12, 54] . Electrophysiologic evaluation can be performed on uncooperative patients and is a more sensitive study, but requires specialized resources and may not fully differentiate myopathy from neuropathy [55] . Muscle biopsy is invasive (although percutaneous biopsy can provide sufficient tissue [56] ) and full evaluation also requires specialized resources, such as electron microscopy. Optimal timing of assessment remains unclear; it appears that electrophysiologic and pathologic changes begin to occur early in most affected patients [27, 57] , but patients may continue to acquire dysfunction throughout the course of critical illness [8] .
Standardized physical examination performed after discharge from intensive care may be sufficient to classify 'clinical weakness' in patients for longitudinal studies focused on natural history. It may be helpful to add an additional standardized measure of strength, such as handgrip dynamometry, which may be more sensitive and is ripe for further study [54] . For studies interested in risk factors, pathophysiology, treatment or prevention, including limited electrophysiologic evaluation will allow inclusion of patients unable to cooperate with strength testing [58 ] , which is important to minimize misclassification and enhance generalizability of findings. Muscle biopsy can be limited to studies of pathophysiology that require a more precise discrimination between CIM and CIP, or that seek insight into molecular biology.
Measurement of ICU risk factors
There clearly is a need for additional, methodologically rigorous studies to evaluate the independent effect of commonly cited risk factors for neuromuscular dysfunction in ICU survivors. Further research is needed regarding the potential effect of patient demographics, the severity and type of critical illness, and ICU therapies on weakness. Given the lack of consistency among analyses of proposed risk factors, greater understanding of the pathophysiology of neuromuscular dysfunction is needed so that novel determinants can be explored in clinical evaluations. Particular attention should be directed to how each factor is measured and modeled using adequately large sample sizes and statistical analyses that adjust for potential confounding factors. Specifically, further evaluation of corticosteroids, in a setting in which blood glucose is tightly controlled, may elucidate whether this therapy has harm or benefit on muscle weakness.
Measurement of functional and quality of life outcomes
In order to assess the association of ICU-acquired neuromuscular dysfunction with long-term outcomes, as well as to assess potential effects of interventions on these outcomes, it is necessary to evaluate survivors after hospital discharge. In designing observational and interventional studies, we must address a number of important questions. When should subjects be evaluated? What measures or instruments should be used for evaluation? What co-existent problems may potentially complicate assessment of HRQOL and functional status?
Timing of patient follow-up is best guided by the research question that investigators are trying to answer. Follow-up studies of survivors of acute lung injury suggest that functional status improves markedly between 3 and 6 months after hospital discharge [2, 59] . On average, recovery appears to plateau by 12 months after hospital discharge, without significant additional improvement between years 1 and 5 [60] . HRQOL appears to improve most rapidly in the first 6 months [2, 61] , but continued improvement has been noted out to 5 years [60] . Therefore, peak functional recovery may be assessed at a single evaluation 12 months after discharge, while studying time to recovery may require collection of several data points in the first year. These suggestions, however, are limited by the relatively small number of patients studied, to date, beyond 1 year after critical illness.
There are a number of studies that evaluated HRQOL after critical illness [2, 3, 59, [62] [63] [64] [65] [66] [67] [68] . The most commonly used instrument is the Medical Outcomes Study Short Form 36 (SF-36) [69,70 ,71] . The SF-36 is a generic (versus disease-specific) measure of HRQOL that evaluates eight domains of physical and mental health. There are many advantages of the SF-36, including its psychometric properties, adaptability for phone administration, and common usage in prior ICU follow-up studies. While it is reasonable to consider other measures of HRQOL [72] , it may be wise to continue using the SF-36 until a new standard emerges.
Few ICU follow-up studies have measured functional status. Previously, both a survey-based assessment of Activities of Daily Living (ADL) [59, 73] and a performance-based test, the 6-min walk test (6MWT) [2, 74] , have been performed. Neither of these tests is ideal. The ADL survey may have a ceiling effect and not detect important functional limitations. The 6MWT is difficult to perform outside of the clinical setting (e.g. during a home visit) and survivors with significant limitation may be unable to participate. The 'best' method to assess functional outcome after critical illness is not clear.
Concomitant neuropsychological problems in ICU survivors may further complicate evaluation of HRQOL and functional outcomes [59, 65] . Cognitive impairment can interfere with subjects' ability to complete questionnaires and follow directions. In addition, psychiatric symptoms, such as posttraumatic stress or depression, may lead to amplification of somatic complaints. To understand the role of weakness on HRQOL and functional outcomes, it may be necessary to evaluate these neuropsychological impairments.
Minimizing loss to follow-up
Loss to follow-up creates selection bias that threatens the internal validity of a research study. This issue is especially challenging in longitudinal studies of ICU survivors when significant physical and mental health morbidities may limit patients' ability to return for follow-up. Investigators designing future studies should review the 'best practices' from prior longitudinal studies to assist in designing a comprehensive program to minimize loss to follow-up [75 ,76-80] . Although quite burdensome, home visits are an integral part of longitudinal studies that require in-person assessment of ICU survivors [2, 75 ]. This issue should be carefully considered when designing outcome measures for future studies since certain tests, such as electromyogram and nerve conduction studies, may be difficult or impossible to perform, in a valid and reliable manner, during a home visit.
Future studies
As the pathophysiology and determinants of neuromuscular dysfunction in ICU survivors are being elucidated, strategies for improving outcomes are also needed. Therapies may provide benefit through preventing or reducing neuromuscular impairment in the ICU or accelerating recovery after ICU discharge. An increased intensity of physical rehabilitation therapy, both in the ICU and after hospital discharge, as well as adjunctive strategies (e.g., electrical stimulation therapy), are potential treatment options requiring further evaluation [81 ,82-91] . Furthermore, assessing the effects of nutritional intake while hospitalized and developing novel pharmacologic agents to stimulate muscle growth and regeneration are worthy of investigation in future studies [2, [92] [93] [94] . Increased understanding of pathophysiologic mechanisms involved in muscle and nerve damage may elucidate potential targets for intervention. It is also essential that studies of short-term and long-term neuromuscular function are integrated into interventional clinical trials in the ICU as both primary and secondary outcome measures. Many ICU therapies could have either expected or unexpected effects (either beneficial or harmful) on nerve and muscle, which may ultimately impact survivors' HRQOL.
Conclusion
While recent studies support the finding that neuromuscular dysfunction is common and important after critical illness, reversible risk factors and approaches to prevention and treatment remain unproven. Pathophysiologic studies implicate disease and treatment associated factors in the development of nerve and muscle damage during critical illness; these factors may provide targets for future studies. Additional studies with improved methodology that study incidence, risk factors and outcomes, as well as test interventions are needed to understand and to improve neuromuscular function and functional outcomes after critical illness.
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